

University of Groningen

Small airway hyperresponsiveness in COPD

Maarsingh, Harm; Bidan, Cecile M.; Brook, Bindi S.; Zuidhof, Annet B.; Elzinga, Carolina R. S.; Smit, Marieke; Oldenburger, Anouk; Gosens, Reinoud; Timens, Wim; Meurs, Herman

Published in:

American Journal of Physiology - Lung Cellular and Molecular Physiology

DOI:

[10.1152/ajplung.00325.2018](https://doi.org/10.1152/ajplung.00325.2018)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Maarsingh, H., Bidan, C. M., Brook, B. S., Zuidhof, A. B., Elzinga, C. R. S., Smit, M., Oldenburger, A., Gosens, R., Timens, W., & Meurs, H. (2019). Small airway hyperresponsiveness in COPD: Relationship between structure and function in lung slices. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, 316(3), L537-L546. <https://doi.org/10.1152/ajplung.00325.2018>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Small Airway Hyperresponsiveness in COPD: Relationship Between Structure and Function in Lung Slices

Harm Maarsingh^{1,2,7,8}, Cécile M. Bidan^{3,4}, Bindi S. Brook⁵, Annet B. Zuidhof^{1,7,8}, Carolina R.S. Elzinga^{1,7,8}, Marieke Smit^{1,6,7}, Anouk Oldenburger^{1,7,8}, Reinoud Gosens^{1,7,8}, Wim Timens^{6,7}, and Herman Meurs^{1,7,8}

¹University of Groningen, Department of Molecular Pharmacology, Groningen, The Netherlands, ²Palm Beach Atlantic University, Lloyd L. Gregory School of Pharmacy, Department of Pharmaceutical Sciences, West Palm Beach, FL, USA, ³Université Grenoble Alpes, CNRS, Laboratoire Interdisciplinaire de Physique (LIPhy), Grenoble, France, ⁴Max Planck Institute of Colloids and Interfaces, Department of Biomaterials, Potsdam, Germany, ⁵University of Nottingham, School of Mathematical Sciences, Nottingham, UK, ⁶University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen, The Netherlands, ⁷University of Groningen, University Medical Center Groningen, Groningen Research Institute of Asthma and COPD, Groningen, The Netherlands, ⁸University of Groningen, Groningen Research Institute of Pharmacy, Groningen, The Netherlands.

Address for Correspondence:

Harm Maarsingh, PhD, Department of Pharmaceutical Sciences, Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, 901 South Flagler Drive, PO Box 24708, West Palm Beach, FL 33414, USA.
E-mail: harm_maarsingh@pba.edu; Phone: +1 561 803 2746; Fax: +1 561 803 2703

26 **Running head:** Small Airway Hyperresponsiveness in COPD

27

28 **New & Noteworthy:** Small airway hyperresponsiveness is demonstrated in
29 precision-cut lung slices from guinea pigs with COPD-like changes induced by
30 chronic lipopolysaccharide exposure and from patients with mild to moderate COPD.
31 In both species, the hyperresponsiveness is not caused by increased airway smooth
32 muscle mass, but may involve parenchymal destruction as well as passive
33 biomechanical changes in the airway wall.

34

35 **Keywords:** airway constriction, airway remodeling, biomechanical modeling,
36 emphysema, human lung

37

38 **ABSTRACT**

39 The direct relationship between pulmonary structural changes and airway
40 hyperresponsiveness (AHR) in chronic obstructive pulmonary disease (COPD) is
41 unclear. We investigated AHR in relation to airway and parenchymal structural
42 changes in a guinea pig model of COPD and in COPD patients.

43 Precision-cut lung slices (PCLS) were prepared from guinea pigs challenged
44 with lipopolysaccharide or saline twice weekly for twelve weeks. Peripheral PCLS
45 were obtained from patients with mild to moderate COPD and non-COPD controls.
46 AHR to methacholine was measured in large and small airways using video-assisted
47 microscopy. Airway smooth muscle mass and alveolar airspace size were determined
48 in the same slices. A mathematical model was used to identify potential changes in
49 biomechanical properties underlying AHR.

50 In guinea pigs, lipopolysaccharide increased the sensitivity of large ($>150\mu\text{m}$)
51 airways towards methacholine by 4.4-fold and the maximal constriction of small
52 airways ($<150\mu\text{m}$) by 1.5-fold. Similarly, increased small airway responsiveness was
53 found in COPD patients. In both lipopolysaccharide-challenged guinea pigs and
54 patients, airway smooth muscle mass was unaltered, whereas increased alveolar
55 airspace correlated with small airway hyperresponsiveness in guinea pigs. Fitting the
56 parameters of the model indicated that COPD weakens matrix mechanical properties
57 and enhances stiffness differences between the airway and the parenchyma, in both
58 species.

59 In conclusion, this study demonstrates small airway hyperresponsiveness in
60 PCLS from COPD patients. These changes may be related to reduced parenchymal
61 retraction forces as well as biomechanical changes in the airway wall. PCLS from
62 lipopolysaccharide-exposed guinea pigs may be useful to study mechanisms of small
63 airway hyperresponsiveness in COPD.

64 INTRODUCTION

65 Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease,
66 characterized by a progressive and partially irreversible decline in lung function and
67 by airway hyperresponsiveness (AHR) (13, 14, 23, 24). Chronic inflammation in
68 COPD causes structural alterations and narrowing of particularly the small airways,
69 and emphysema, characterized by parenchymal destruction. It has been proposed
70 that loss of lung function and AHR may result from small airway remodeling -
71 including increased airway smooth muscle (ASM) mass - and from loss of elastic
72 recoil by parenchymal damage (13, 14, 23, 24). These structural changes may differ
73 between patients, depending on various factors (13).

74 Although this hypothesis has been around for several decades, evidence for a
75 direct relationship between structural changes in the lung and small airway function is
76 still lacking. Measurement of airway mechanics in precision-cut lung slices (PCLS)
77 using video-assisted microscopy *ex vivo* (19, 26) may be highly instrumental in
78 investigating the impact of structural changes on airway responsiveness. Microscopic
79 visualization allows to perform these studies even in the smallest airways, a major
80 breakthrough for the study of small airway function.

81 Limited studies on small airway mechanics in PCLS from animal models of
82 COPD are known (5, 7, 8, 16, 17, 33). In one of these studies, enhanced small
83 airway responsiveness to carbachol and serotonin was found in rats after chronic *in*
84 *vivo* exposure to tobacco smoke, which was associated with increased airway wall α -
85 smooth muscle actin (α -SMA) content (5). In contrast, no small airway
86 hyperresponsiveness was observed in mice after short-term exposure to cigarette
87 smoke (8), elastase (17) or lipopolysaccharide (LPS) (7). However, exposure of
88 mouse PCLS to elastase or collagenase *ex vivo* induced AHR to acetylcholine and

methacholine (16, 17, 33). Mechanical studies in PCLS from patients with COPD have thus far not been described.

In this study, we investigated alterations in the responsiveness of large and small intrapulmonary airways to methacholine in PCLS obtained from a guinea pig model of COPD induced by chronic LPS exposure (22). This model resembles COPD patho(physio)logy in several ways: the presence of neutrophilic inflammation, mucus hypersecretion, emphysema, small airway fibrosis and vascular remodeling (22). In addition, guinea pig lungs contain both large and small airways. We also determined the relationship between structural components of the airways and parenchyma (ASM mass and parenchymal integrity) and responsiveness of the individual airways within the same PCLS. Importantly, this relationship was also assessed for small airways in lung slices obtained from human control subjects and patients with mild to moderate COPD. Finally, we used a multiscale model of an airway embedded in parenchyma (12) to identify possible alterations in biomechanical properties that could underlie the observations in PCLS.

METHODS

Animals

Outbred, male, specified pathogen-free Dunkin Hartley guinea pigs (Harlan, Heathfield, UK) weighing 350–400 g were used. The animals were housed in pairs under a 12 hour light/dark cycle in a temperature- and humidity-controlled room with food and tap water ad libitum. All animal care and experimental procedures complied with the animal protection and welfare guidelines and were approved by the Institutional Animal Care and Use Committee of the University of Groningen, The Netherlands, and are reported in compliance with the ARRIVE guidelines (18).

Lipopolysaccharide instillation

At the start of the protocol, guinea pigs were randomly selected to be challenged by intranasal instillation of 200 μ L lipopolysaccharide (LPS, Sigma-Aldrich, St. Louis, MO, USA, 5 mg/mL in sterile saline) or 200 μ L sterile saline (control group) twice weekly for 12 consecutive weeks as described by Pera *et al.* (22). To this aim, conscious guinea pigs were held in an upright position, while the LPS solution was slowly instilled. After the intranasally instilled solution was aspirated, the animals were kept in the upright position for an additional 2 min to allow sufficient spreading of the fluid throughout the airways. Animal welfare was monitored by weighing the animals prior to each intranasal instillation; no animals needed to be withdrawn from the protocol. Previous studies have demonstrated that guinea pigs challenged with LPS are a good model for COPD as it induces various inflammatory and pathological changes closely mimicking COPD (22, 32).

Guinea pig lung slices

24 h after the last challenge, precision-cut lung slices were prepared as described previously (20, 25). The animals were sacrificed using an overdose of pentobarbital (Euthasol 20%, Produlab Pharma, Raamsdonkveer, The Netherlands) followed by exsanguination via the aorta abdominalis. The trachea was cannulated, the diaphragm was opened and the lungs were filled through the cannula at constant pressure with a low melting-point agarose (Gerbu Biotechnik GmbH, Weiblingen, Germany) solution (1.5%) in a buffer containing 0.9 mM CaCl_2 , 0.4 mM MgSO_4 , 2.7 mM KCl, 58.2 mM NaCl, 0.6 mM NaH_2PO_4 , 8.4 mM glucose, 13 mM NaHCO_3 , 12.6 mM Hepes, 0.5 mM sodium pyruvate, 1 mM glutamine, MEM-amino acids mixture (1:50), and MEM-vitamins mixture (1:100), pH = 7.2. The agarose solution contained 1 μ M isoproterenol to prevent post-mortem constriction (25). After filling, the lungs

were covered with ice for at least 30 min, in order to solidify the agarose for slicing. The lungs were removed and cylindrical tissue cores were prepared from the lobes using a rotating sharpened metal tube (diameter 15 mm), followed by slicing the tissue in ice cold buffer composed of 1.8 mM CaCl₂, 0.8 mM MgSO₄, 5.4 mM KCl, 116.4 mM NaCl, 1.2 mM NaH₂PO₄, 16.7 mM glucose, 26.1 mM NaHCO₃, 25.2 mM Hepes, and 1 μM isoproterenol, pH =7.2, using a tissue slicer (CompresstomeTM VF-300 microtome, Precisionary Instruments, San Jose CA, USA). Lung slices were cut at a thickness of 500 μm and washed several times to remove the agarose and cell debris from the tissue. Slices were incubated in a 12-wells plate overnight in minimal essential medium composed of 1.8 mM CaCl₂, 0.8 mM MgSO₄, 5.4 mM KCl, 116.4 mM NaCl, 1.2 mM NaH₂PO₄, 16.7 mM glucose, 26.1 mM NaHCO₃, 25.2 mM Hepes, 0.5 mM sodium pyruvate, 1 mM glutamine, MEM-amino acids mixture (1:50), and MEM-vitamins mixture (1:100), pH = 7.2, containing penicillin and streptomycin (1:100), at 37°C in a CO₂- and humidity-controlled atmosphere.

Human lung slices

Peripheral lung tissue from COPD GOLD 1 (n=4) and GOLD 2 (n=3) patients and from non-COPD control subjects (n=5) was obtained from subjects undergoing surgery for lung cancer using tumor-free tissue far from the tumor site, except one control that was obtained from a non-transplanted donor lung. All tissue was collected according to the Research Code of the University Medical Center Groningen (<https://www.umcg.nl/SiteCollectionDocuments/English/Researchcode/UMCG-Researchcode,%20basic%20principles%202013.pdf>) and national ethical and professional guidelines ('Code of conduct', Dutch federation of biomedical scientific societies, <http://www.federa.org>). Characteristics of the subjects are shown in Table 1

of the printed version. After placing on a metal plate on ice, 2% low-melting agarose was slowly injected into the tissue, evenly distributed at several sites of the tissue, essentially as described by Sturton *et al.* (28). Subsequently, the tissue was covered with ice for 15 min. Cylindrical cores of 15 mm in diameter were prepared, cut with a tissue slicer into 500 μm thin slices, and processed as described above for guinea pig lung slices.

Airway responsiveness measurements

After washing the slices in medium airway responsiveness to methacholine (10^{-9} - $3 \cdot 10^{-3}$ M, using cumulative concentrations in half-log increments) was assessed in 1-6 slices per animal or human donor, using video-assisted microscopy (Nikon Eclipse TS 100). To this aim individual slices were positioned under the microscope using a 24-wells plate, mechanically maintained with a Teflon ring of 7 mm inner diameter and 10 mm outer diameter, and covered with 1 mL of minimal essential medium. Only slices were used with approximately circular airways (longest/shortest diameter < 2) and with ciliary beating as an indication of intact epithelium and viability of the slices. In guinea pig slices methacholine-induced contraction was measured both in large and small airways (in this species defined by diameters larger and smaller than 150 μm , respectively), whereas in human slices only small airways ($< 500 \mu\text{m}$) were studied. To quantify airway luminal area, image acquisition software (NIS-Elements, Nikon) was used. Images of the airways were acquired every 2 sec during the whole course of the experiment, starting 2 min before the addition of the first dose of contracting agent to allow for baseline measurements of the airway caliber. Airway constriction was then expressed as percentage of the initial (baseline) area of the airway lumen. Per slice, one airway was measured. After establishing the

cumulative concentration-response curve, slices were thoroughly washed in fresh medium.

Histochemistry

After a subsequent overnight washout, lung slices were placed in cassettes supported by biopsy foam pads, fixed in 10% formalin for 24 h, and embedded in paraffin. Paraffin sections (4 μm thin) were cut from the slices to assess remodeling parameters. Airway smooth muscle mass was determined by α -SMA staining. After deparaffinization, endogenous peroxidase was blocked for 30 min using 0.3% H_2O_2 in phosphate buffered saline (PBS; 140 mM NaCl, 2.6 mM KCl, 1.4 mM KH_2PO_4 , 8.1 mM Na_2HPO_4 , pH7.4). After 5 minutes washing with PBS, the sections were cooked in 10 mM Na_3 -citrate buffer, pH 6, for 5 min using a pressure cooker. Sections were then incubated for 15 min with 1% triton-x100 in PBS, and washed three times with PBS afterwards. The sections were incubated for two min with mouse anti- α -smooth muscle actin antibody (Sigma-Aldrich, St. Louis, MO, USA), diluted 1:1000 in 1% bovine serum albumin (BSA) in PBS. Subsequently, the sections were incubated for 30 min with 1% BSA in PBS and washed three times with PBS. The secondary antibody (horse radish peroxidase-conjugated goat anti-mouse IgG antibody (Sigma-Aldrich, St. Louis, MO, USA), 1:200 in 1 % BSA in PBS) was incubated for 30 min and washed three times with PBS. 3,3'-diaminobenzidine (DAB) was dissolved in PBS at a concentration of 0.34 mg/ mL and 0.3% H_2O_2 was added just before use. After 20 min incubation, sections were washed with ultra-pure water and counterstained with haematoxylin. After 5 min rinsing under running tap water, sections were dehydrated in ethanol and covered with mounting medium. Airways were digitally photographed and analyzed using Image J software (National Institutes of Health, Bethesda, MD). The positively stained area (μm^2) was normalized to the

square of the basement membrane length (μm^2). For evaluation of emphysema, paraffin sections were stained with haematoxylin and eosin. Mean linear intercept (MLI) was determined as a measure of alveolar airspace size as described previously (21), using 20 to 25 photomicroscopic images (magnification 200x) per slice.

Mathematical model

A multiscale biomechanical model previously developed (12) was used to couple contractile force generated by airway smooth muscle at the cell level and the narrowing of a non-linearly elastic airway wall embedded in parenchyma. Briefly, this model considers the airway as an axisymmetric thick-walled cylinder of fixed length in a plane-strain approximation (with no axial displacement) and consists of two layers representing the airway wall and the surrounding parenchymal tissue. The parenchyma is assumed to be a compressible linear elastic material with compressibility ν , which can be reduced to mimic connective tissue damage associated with COPD. The airway wall is considered to be an incompressible nonlinear elastic material of modulus represented by the variable γ when parametrized relative to the elastic modulus of the parenchyma at zero stress. As such, an increase in γ may be interpreted as an increase of airway elasticity modulated by matrix structure, and/or a degradation of elastin in the parenchyma. The finite thickness χ of the airway wall is normalized by the radius of the lumen. Fibers embedded as rings in the airway wall represent the ASM bundles and the collagen-dominated ECM; they are thus assumed to passively stiffen as collagen is recruited upon airway inflation (uncrimping of collagen fibers and thus increased load-bearing) and to actively generate a contractile force upon ASM activation. The passive stiffness of these fibers is governed by two parameters C_1 and C_2 : C_1 takes into account the density of fibers whereas C_2 governs the nonlinear increase in the

stiffness of the fibers as they stretch. The active contribution of the ASM in the mechanical properties of the airway results from cellular forces generated by contractile units made of a myosin filament and adjacent actin filaments. β is a parameter accounting for the volume fraction of the ASM cells in the airway, the number of parallel myosin filaments within a single ASM cell and also indirectly for the density of receptors within an ASM cell. Multiplying β by the contractile force generated by a single myosin filament determined via the Huxley-Hai-Murphy (HHM) model, results in the overall contractile force of the ASM. Note that a fixed pre-stress is also applied to mimic the inflation of the lung in the preparation of the PCLS. Additionally, displacement and radial stress are assumed to be always continuous at the boundary between the airway wall and the parenchyma.

First, simulations using this model were used to generate concentration-response curves and identify a baseline set of parameters fitting the concentration-response curves from the human and guinea pig control data. Further simulations were then carried out to determine the changes required in the 6 parameters above to generate similar changes to those observed in the dose-response curves of human COPD and LPS challenged guinea pig PCLS. The parameter changes identified in this way enable inference of the structural changes that could have occurred to generate the observations. The MATLAB scripts for running model simulations as described here can be obtained by contacting the corresponding author of Hiorns et al, 2014 (12).

Data analysis

Data are expressed as means \pm SEM. An n=1 represents the average of the measurements of each airway classification per animal. A power analysis ($\mu_1 - \mu_2 = 40$, $\sigma = 30$, $\alpha = 0.5$, $\text{power} = 0.8$) determined that 9 animals were to be

included per group for the constriction experiments. Per group, 10 animals were included to anticipate an experimental dropout rate of 10% and which allowed for housing all guinea pigs in pairs. Statistical differences were determined by two-way ANOVA, by paired or unpaired Student's t-test or by Mann-Whitney U test as appropriate. Correlations were determined using Pearson's correlation coefficient test. Differences were considered statistically significant when $P < 0.05$.

RESULTS

Airway responsiveness in guinea pigs

Methacholine induced a concentration-dependent constriction of intrapulmonary large and small airways in PCLS obtained from saline- and LPS-challenged guinea pigs (Fig 1A and 1B). Interestingly, the maximal constriction (E_{\max}) of the large airways from the saline-challenged controls was 1.8-fold higher compared to that of small airways of the same animals ($P < 0.001$), without a difference in sensitivity (pD_2) towards methacholine (Table 2). In the large airways of PCLS from LPS-challenged animals, a 4.4-fold higher sensitivity towards methacholine was observed compared to large airways from saline-challenged controls ($P < 0.01$), with a small increase in maximal effect ($P < 0.05$, Fig. 1A, Table 2). The maximal constriction of small airways from LPS-challenged animals was 1.5-fold higher as compared to saline-challenged controls ($P < 0.001$), without a difference in sensitivity towards methacholine (Fig. 1B, Table 2). Airway sizes among saline- and LPS-challenged guinea pigs, respectively, were similar for large ($265 \pm 16 \mu\text{m}$ vs $264 \pm 15 \mu\text{m}$) and small ($112 \pm 5 \mu\text{m}$ vs $111 \pm 4 \mu\text{m}$).

295 *ASM mass and alveolar airspace size in guinea pigs*

296 Compared to saline-challenged controls, repeated LPS challenge did not alter ASM
297 mass of either large or small airways as determined by α -SMA-positive area (Fig.
298 2A). Consequently, no correlations between E_{\max} or pD_2 and ASM mass were
299 observed (Fig. 2B).

300 Repeated LPS challenge did induce a trend towards an increase in MLI as
301 compared to saline-challenged animals ($P < 0.10$, Fig. 2C). Interestingly, a significant
302 correlation between MLI and E_{\max} of small, but not large, airways was found (Fig.
303 2D). No correlations between MLI and pD_2 -values were observed (Fig. 2D).

305 *Small airway responsiveness in human PCLS*

306 The responsiveness of human peripheral control airways to methacholine (Fig. 3,
307 Table 2) was similar to that in the small airways from saline-challenged guinea pigs
308 (Fig. 1B, Table 2). A 1.5-fold higher maximal constriction ($P < 0.05$) was observed in
309 lung slices obtained from patients with COPD as compared to control subjects,
310 without a difference in pD_2 (Fig. 3, Table 2). There was no difference between the
311 airway diameters of control subjects ($273 \pm 59 \mu\text{m}$) and COPD patients ($227 \pm 48 \mu\text{m}$).
312 Remarkably, the hyperresponsiveness of the COPD airways was identical to that
313 observed in the small airways of the LPS-challenged guinea pigs.

315 *ASM mass and alveolar airspace size in human PCLS*

316 No difference in ASM mass was found between slices from control subjects and
317 subjects with COPD (Fig. 4A). A 1.2-fold higher MLI was measured in the lung slices
318 of the COPD patients as compared to the control subjects ($P < 0.05$, Fig. 4C). There
319 were no significant correlations between the α -SMA-positive area (Fig. 4B) or the MLI
320 (Fig. 4D) and the E_{\max}/pD_2 of methacholine-induced airway constriction.

Changes in biomechanical properties in PCLS from COPD patients and LPS-challenged guinea pigs

In the model, the biomechanical properties of the airway wall (ASM and collagen fibers) and parenchyma are characterized by the parameters listed in Figure 5A and Table 3 (12). Any structural changes in the airway or parenchyma would modify these parameters, and impact the mechanical response to agonist challenge. Baseline values of these parameters were first obtained by fitting a simulated concentration-contraction curve to the experimental concentration-contraction one from human control subjects (Fig. 5B, Table 3). The effect of changing one parameter at a time was then explored. Similar baseline airway diameters and ASM mass measured between control and COPD slices justified keeping the airway wall thickness (χ) and ASM density and/or muscarinic receptor density (β) at baseline values for all human data simulations. Simulating reduction in collagen fibers density within the airway wall (C_1) or in the extent to which they are recruited (C_2) generated minimal hyperresponsiveness (Fig. 5B). Similarly, reducing the compressibility (ν) or the stiffness (increased γ) of the parenchyma relative to the airway wall generated small levels of hyperresponsiveness (Fig. 5B). Mimicking structural changes to the collagen matrix within the airway wall without changes to the parenchyma, and *vice versa*, had thus a limited impact. In contrast, all these parametric changes implemented simultaneously induced a significant shift in the simulated dose-response curve, which matched the experimental data obtained on COPD slices (Fig. 5B; Table 3). This suggests that structural changes to the matrix occurring in COPD (2) affect both the airway wall and the parenchyma, modifying the effective mechanical properties of both compartments.

For guinea pig slices, model baseline parameters were first fitted to the saline-challenged concentration-response curve for small airways (Fig. 5C, Table 3). Higher ASM/muscarinic receptor density (β) and non-zero inflation pressure were required to fit the guinea pig data. Changes in both airway wall and parenchymal properties were needed to match the LPS-challenged guinea pig experimental concentration-response curve for small airways. Specifically, a slightly thicker airway was needed (parameter set 1 or 2), together with reduced collagen fiber density and parenchymal compressibility and stiffness relative to the baseline guinea pig parameters (Fig. 5C, Table 3). In the case of the saline-treated guinea pig data for large airways, simulated dose-response curves fitted to the experimental dose-response curve (Fig. 5D, Table 3) suggested that slightly thicker airways (χ) as well as significantly increased ASM/muscarinic receptor density (β) are present. The biomechanical model was unable to generate dose-response curves for the LPS-treated guinea pig data for the large airways.

DISCUSSION

This study successfully shows the high potential of guinea pig and human PCLS in studying (small) airway mechanics in relation to tissue remodeling in COPD. Both in PCLS from a guinea pig model of LPS-induced COPD and in PCLS from patients with mild to moderate COPD we demonstrated small airway hyperresponsiveness to methacholine, which is not caused by increased ASM mass, but may be related to reduced parenchymal stiffness and compressibility involving increased alveolar airspace size and reduced stiffness of the passive components of the airway wall.

In PCLS from LPS-challenged guinea pigs, a 1.5-fold increase in maximal methacholine-induced airway constriction was observed in the small airways, without a change in sensitivity towards the agonist. Only a small increase in E_{\max} was

observed in the large airways of LPS-challenged animals, due to the pronounced (90%) methacholine-induced constriction of these airways in the saline group. An increase in pD_2 was observed in large airways. Further studies indicated that emphysema may be involved in LPS-induced small airway hyperresponsiveness, as increased alveolar airspace sizes were positively correlated with the E_{max} in small airways within the same PCLS. No correlation between these parameters was found for the large airways; neither was there a correlation between MLI and pD_2 values for either airway type. From a pharmacological point of view, these results indicate that post-receptor changes are involved in the increased small airway constriction to methacholine, which may at least partially be caused by structural changes in the parenchyma. Since ASM mass was unaltered after LPS challenge for either airway type and there was no correlation between ASM mass and airway responsiveness, ASM mass *per se* is not an important determinant of AHR in this model.

Remarkably, we found a larger maximal methacholine-induced narrowing of the large airways as compared to the small airways, both after saline and LPS challenge. Studies in rat PCLS demonstrated that airway responsiveness (reduction in airway luminal area) towards electrical field stimulation is greater in large airways compared to small airways (28), whereas no differences in the responsiveness to methacholine were observed (19). We did not observe significant differences in sensitivity (pD_2) towards methacholine between large and small airways in PCLS obtained from saline-challenged guinea pigs. However, in rats the sensitivity to methacholine is greater in the large airways than in the small airways (19), whereas the opposite has been observed in mice (6). Since different techniques were used in the latter study (6) to determine the constriction of trachea (contractility) and small airways (airway area), the responsiveness (E_{max}) of large and small airways cannot be compared. The increased responsiveness of the large airways in guinea pig PCLS

is not related to the ASM mass, since – similar to human airways (9) - the relative ASM thickness was smaller in the large airways. Previous findings using the same animal model demonstrated that repeated LPS challenge did not alter the active tension of isolated airways induced by either methacholine or histamine (Pera et al, unpublished observations) further supporting the contribution of structural changes in the parenchyma to the observed LPS-induced AHR.

This study also describes the first measurements of airway mechanics in PCLS from COPD patients. Remarkably, PCLS of human control subjects demonstrated a similar responsiveness of the peripheral airways to methacholine as the small airways of saline-challenged guinea pigs. This confirms previous observations that guinea pig PCLS are an excellent physiological and pharmacological model for human tissue (25, 27). Similar to the guinea pig data, hyperresponsiveness to methacholine – characterized by an increased E_{\max} - of peripheral airways from patients with mild to moderate COPD (GOLD 1 and 2) was observed. In line with previous studies (13) and the guinea pig model, no changes in ASM mass in the small airways were observed in patients with mild to moderate COPD. Slices from the COPD patients did reveal a small but significantly enhanced MLI, however, no significant correlation between MLI and E_{\max} was observed. This may be due to both the low number of subjects and the involvement of additional factors, such as microstructural changes in the extracellular matrix components, which may similarly impact the mechanical behavior of the airways and the parenchyma (2).

In the alveolar and small airway walls of COPD patients reduced expression of elastin and decorin, a proteoglycan involved in the assembly of collagen fibers, and increased expression of collagen have been described (2, 11, 14, 34, 36). Similar observations have been reported for smoke- and LPS-induced guinea pig models of

COPD characterized by small airway remodeling and emphysema (4, 15, 23). As the mechanical properties of collagen fibers highly depend on the quality of their assembly, higher collagen content does not necessarily lead to a stiffer tissue (30). Thus, loss of decorin as observed in COPD (14, 34, 36) will lead to disorganization and sliding of collagen fibers despite an increase of the matrix protein. Indeed, imaging revealed structural differences of parenchymal collagen and elastin between non-diseased subjects and COPD patients (1, 31). Moreover, PCLS studies in mice showed disorganized and stretched parenchymal collagen fibers upon elastin degradation (33). Consequences of extracellular matrix changes for mechanical functions of the lung have been explored in PCLS *ex vivo* and revealed that airway responsiveness is enhanced upon protease-induced degradation of elastin or collagen fibers (16, 33).

The emerging hypothesis of a central role of extracellular matrix remodeling in AHR (2, 3, 30) is further supported by a biomechanical model (12). The contribution on airway responsiveness of the active ASM cells and the passive airway and parenchymal matrices could be assessed separately by parametric changes. Simulations of the contraction experiments could fit the COPD experimental data only when changes to passive mechanical properties occurred in both the airway wall and the parenchyma as compared to control PCLS. The relative weakening of the extracellular matrix in COPD suggested by these changes, potentially including elastin degradation, decorin loss and disorganization of collagen fibers, is consistent with both the observation of hyperresponsiveness despite a conserved airway smooth muscle mass and with the increased MLI in COPD patients and LPS-challenged guinea pigs.

Guinea pig has a thicker ASM layer in comparison to most species, which could explain why the biomechanical model could not generate concentration-

contraction curves for the LPS-treated guinea pig data for the large airways and would potentially require distinct baseline characteristics. Indeed, the model parameter fit suggests that in the control data both airway wall thickness and ASM density needed to be greater than the corresponding human parameters (Table 3). Another explanation for the failure of the model to simulate the LPS-treated guinea pig data for the large airways, is a potentially higher baseline tone which the model is not able to account for. Additionally, any stretch dependent changes in the parameters (such as decreased tethering in response to strong contraction as a result of LPS-modified ECM) are not accounted for in the current model, but could be an explanation for the strong dose response.

Only few studies reported on small airway structure and responsiveness in PCLS in animal models with characteristics of COPD. Thus, cigarette smoke exposure of rats during 8-16 weeks increased the sensitivity but not the E_{\max} of intrapulmonary airways to carbachol and serotonin, and increased ASM mass, which correlated with the sensitivity to serotonin, but not carbachol (5). Although we did not find an increased ASM mass in our model or in our patients with mild to moderate COPD, the absence of a correlation between ASM mass and hyperresponsiveness to the muscarinic agonist (5) corresponds to our observations. No changes in sensitivity to serotonin or methacholine were found after *acute* exposure of the rats to cigarette smoke (5), in line with a recent study on acute cigarette smoke exposure in mice (17). In the latter study, a change in the contraction pattern to serotonin, but not to methacholine, was observed that was associated with a change in ryanodine receptor expression (8). Although the acute models were characterized by cigarette smoke-induced inflammation, they are highly unlikely to demonstrate small airway remodeling and emphysema that are important for AHR in COPD. Similarly, airway hyperresponsiveness was not induced in PCLS following *acute* exposure of mice to

LPS, a pro-inflammatory contaminant from gram-negative bacteria in organic dusts and cigarette smoke that has been associated with the development of COPD as well as with bacterial infection-induced exacerbations of COPD (10, 21, 22). However, chronic LPS exposure induced COPD-like inflammation, small airway remodeling and emphysema in mice and guinea pigs (22, 32, 35). The present study indicates that biomechanical changes involved in small airway hyperresponsiveness in chronically LPS-exposed guinea pigs translate to small airway hyperresponsiveness in patients with COPD.

Regarding the 3Rs of the use of animals in biomedical research (18), the current method of studying airway responsiveness in PCLS represents both refinement and reduction. Airway responses of small and large airways to (multiple) experimental drugs can be individually measured in different PCLS from the same animal, thus lowering the number of animals needed, whereas refinement is achieved by measuring AHR *ex vivo* rather than *in vivo*. Moreover, linking mathematical modeling with the functional studies may lead to future reduction of animals needed to predict outcomes.

In conclusion, this is the first study demonstrating small airway hyperresponsiveness in PCLS from patients with mild to moderate COPD, which appears not to be caused by increased airway smooth muscle mass, but rather to be related to reduced parenchymal retraction forces and reduced passive stiffness of the airway wall. In addition, we found evidence that PCLS from chronically LPS-exposed guinea pigs can serve as a useful model to study mechanisms of small airway hyperresponsiveness in mild and moderate COPD.

ACKNOWLEDGEMENTS

We thank Dr. Ramaswamy Krishnan (Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA) for helpful discussions.

GRANTS

This study was supported by the Stichting Astma Bestrijding (grant no. 2010-015 to Harm Maarsingh, Reinoud Gosens, Wim Timens and Herman Meurs), and the Medical Research Council UK (grant no. MR/M004643/1 to Bindi S. Brook).

DISCLOSURES

Part of this study was supported by a grant from Novartis UK.

AUTHOR CONTRIBUTIONS

H.Ma., H.Me., R.G., W.T., C.M.B., and B.S.B. conceived and designed the experiments; H.Ma., A.B.Z., C.R.S.E., M.S., A.O., C.M.B., and B.S.B. performed the experiments ; H.Ma., H.Me., A.B.Z., M.S., W.T., C.M.B., and B.S.B. analyzed the data; H.Ma., H.Me., C.M.B., and B.S.B. drafted the manuscript; all authors read, critically revised and approved the final manuscript.

REFERENCES

1. **Abraham T, Hogg J.** Extracellular matrix remodeling of lung alveolar walls in three dimensional space identified using second harmonic generation and multiphoton excitation fluorescence. *J Struct Biol* 171: 189-196, 2010.
2. **Bidan C, Veldsink AC, Meurs H, Gosens R.** Airway and extracellular matrix mechanics in COPD. *Front Physiol* 6: 346, 2015.
3. **Burgess JK, Mauad T, Tjin G, Karlsson JC, Westergren-Thorsson G.** The extracellular matrix - the under-recognized element in lung disease? *J Pathol* 240: 397-409, 2016.
4. **Churg A, Wang R, Wang X, Onnervik PO, Thim K, Wright JL.** Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. *Thorax* 62: 706-713, 2007.
5. **Cooper PR, Poll CT, Barnes PJ, Sturton RG.** Involvement of IL-13 in tobacco smoke-induced changes in the structure and function of rat intrapulmonary airways. *Am J Respir Cell Mol Biol* 43: 220-226, 2010.
6. **Donovan C, Royce SG, Esposito J, Tran J, Ibrahim ZA, Tang ML, Bailey S, Bourke JE.** Differential effects of allergen challenge on large and small airway reactivity in mice. *PLoS One* 8:e74101, 2013.
7. **Donovan C, Royce SG, Vlahos R, Bourke JE.** Lipopolysaccharide does not alter small airway reactivity in mouse lung slices. *PloS One* 10: e0122069, 2015.
8. **Donovan C, Seow HJ, Royce SG, Bourke JE, Vlahos R.** Alteration of airway reactivity and reduction of ryanodine receptor expression by cigarette smoke in mice. *Am J Respir Cell Mol Biol* 53: 471-478, 2015.

- 542 9. **Ebina M, Yaegashi H, Takahashi T, Motomiya M, Tanemura M.** Distribution of
543 smooth muscles along the bronchial tree. A morphometric study of ordinary
544 autopsy lungs. *Am Rev Respir Dis* 141: 1322-1326, 1990.
- 545 10. **Eduard W, Pearce N, Douwes J.** Chronic bronchitis, COPD, and lung function in
546 farmers: the role of biological agents. *Chest* 136: 716-725, 2009.
- 547 11. **Eurlings IM, Dentener MA, Cleutjens JP, Peutz CJ, Rohde GG, Wouters EF,**
548 **Reynaert NL.** Similar matrix alterations in alveolar and small airway walls of
549 COPD patients. *BMC Pulm Med* 14: 90, 2014.
- 550 12. **Hiorns JE, Jensen OE, Brook BS.** Nonlinear compliance modulates dynamic
551 bronchoconstriction in a multiscale airway model. *Biophysic J* 107: 3030–3042,
552 2014.
- 553 13. **Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack**
554 **RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD.** The nature of small-airway
555 obstruction in chronic obstructive pulmonary disease. *New Engl J Med* 350:
556 2645-2653, 2004.
- 557 14. **Hogg JC, Timens W.** The pathology of chronic obstructive pulmonary disease.
558 *Annu Rev Pathol* 4: 435-459, 2009.
- 559 15. **Johnson FJ, Reynolds LJ, Toward TJ.** Elastolytic activity and alveolar epithelial
560 type-1 cell damage after chronic LPS inhalation: effects of dexamethasone and
561 rolipram. *Toxicol Appl Pharmacol* 207: 257-265, 2005.
- 562 16. **Kahn MA, Ellis R, Inman MD, Bates JHT, Sanderson MJ, Janssen LJ.**
563 Influence of airway wall stiffness and parenchymal tethering on the dynamics of
564 bronchoconstriction. *Am J Physiol Lung Cell Mol Physiol* 299: L98-L108, 2010.

- 565 17. **Kahn MA, Klanpour S, Stämpfli MR, Janssen LJ.** Kinetics of in vitro
566 bronchoconstriction in an elastolytic mouse model of emphysema. *Eur Respir J*
567 30: 691-700, 2007.
- 568 18. **Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG.** Improving
569 bioscience research reporting: the ARRIVE guidelines for reporting animal
570 research. *PLoS Biol* 29: e1000412, 2010.
- 571 19. **Martin C, Uhlig S, Ullrich V.** Videomicroscopy of methacholine-induced
572 contraction of individual airways in precision-cut lung slices. *Eur Respir J* 9: 2479-
573 287, 1996.
- 574 20. **Oenema TA, Maarsingh H, Smit M, Groothuis GM, Meurs H, Gosens R.**
575 Bronchoconstriction Induces TGF- β release and airway remodelling in guinea pig
576 lung slices. *PLoS One* 26: 8(6): e65580, 2013.
- 577 21. **Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha**
578 **JA.** Relationship between bacterial colonisation and the frequency, character,
579 and severity of COPD exacerbations. *Thorax* 57: 759-764, 2002.
- 580 22. **Pera T, Zuidhof A, Valadas J, Smit M, Schoemaker RG, Gosens R,**
581 **Maarsingh H, Zaagsma J, Meurs H.** Tiotropium inhibits pulmonary inflammation
582 and remodelling in a guinea pig model of COPD. *Eur Respir J* 38: 789-796, 2011.
- 583 23. **Postma DS, Kerstjens HAM.** Characteristics of airway hyperresponsiveness in
584 asthma and chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*
585 158: S187-192, 1998.
- 586 24. **Postma DS, Timens W.** Remodeling in asthma and chronic obstructive
587 pulmonary disease. *Proc Am Thorac Soc* 3: 434-439, 2006.

- 588 25. **Ressmeyer AR, Larsson AK, Vollmer E, Dahlén SE, Uhlig S, Martin C.**
589 Characterisation of guinea pig precision-cut lung slices: comparison with human
590 tissues. *Eur Respir J* 28: 603-611, 2006.
- 591 26. **Sanderson MJ.** Exploring lung physiology in health and disease with lung slices.
592 *Pulm Pharmacol Ther* 24: 452-465, 2011.
- 593 27. **Schlepütz M, Rieg AD, Seehase S, Spillner J, Perez-Bouza A, Braunschweig**
594 **T, Schroeder T, Bernau M, Lambermont V, Schlumbohm C, Sewald K,**
595 **Autschbach R, Braun A, Kramer BW, Uhlig S, Martin C.** Neurally mediated
596 airway constriction in human and other species: a comparative study using
597 precision-cut lung slices (PCLS). *PLoS One* 7: e47344, 2012.
- 598 28. **Schlepütz M, Uhlig S, Martin C.** Electric field stimulation of precision-cut lung
599 slices. *J Appl Physiol (1985)* 110:545-54, 2011.
- 600 29. **Sturton RG, Trifilieff A, Nicholson AG, Barnes PJ.** Pharmacological
601 characterization of indacaterol, a novel once daily inhaled beta-2 adrenoceptor
602 agonist, on small airways in human and rat precision-cut lung slices. *J Pharmacol*
603 *Exp Ther* 324: 270-275, 2008.
- 604 30. **Suki B, Bates JH.** Extracellular matrix mechanics in lung parenchymal diseases.
605 *Respir Physiol Neurobiol* 163: 33-43, 2008.
- 606 31. **Tjin G, Xu P, Kable SH, Kable EP, Burgess JK.** Quantification of collagen I in
607 airway tissues using second harmonic generation. *J Biomed Opt* 19: 36005,
608 2014.
- 609 32. **Toward TJ, Broadley KJ.** Goblet cell hyperplasia, airway function, and leukocyte
610 infiltration after chronic lipopolysaccharide exposure in conscious guinea pigs:

- 611 effects of rolipram and dexamethasone. *J Pharmacol Exp Ther* 302: 814-821,
612 2002.
- 613 33. **Van Dijk EM, Culha S, Menzen MH, Bidan CM, Gosens R.** Elastase-induced
614 parenchymal disruption and airway hyperresponsiveness in mouse precision cut
615 lung slices: toward an ex vivo COPD model. *Front Physiol* 7: 657, 2017.
- 616 34. **Van Straaten JF, Coers W, Noordhoek JA, Huitema S, Flipsen JT, Kauffman**
617 **HF, Timens W, Postma DS.** Proteoglycan changes in the extracellular matrix of
618 lung tissue from patients with pulmonary emphysema. *Mod Pathol* 12: 697-705,
619 1999.
- 620 35. **Vernooy JH, Dentener MA, van Suylen RJ, Buurman WA, Wouters EF.** Long-
621 term intratracheal lipopolysaccharide exposure in mice results in chronic lung
622 inflammation and persistent pathology. *Am J Respir Cell Mol Biol* 26: 152-159,
623 2002.
- 624 36. **Zandvoort A, Postma DS, Jonker MR, Noordhoek JA, Vos JT, van der Geld**
625 **YM, Timens W.** Altered expression of the Smad signalling pathway: implications
626 for COPD pathogenesis. *Eur Respir J* 28: 533-541, 2006.

TABLES

Table 1. Clinical data

	Control subjects	COPD patients
Number of subjects	5*	7
Age (years) [†]	65 (42-69)	66 (42-69)
Male/female [†]	2/2	5/2
Ex-/current smoker [†]	3/1	4/3
Pack-years ^{†§}	40 (28-52)	50 (20-54)
FEV ₁ (% predicted) [†]	109.5 (87-122)	89 (58-115)
FEV ₁ /FVC [†]	74.2 (69.4-84.2)	60.1 (52.5-67.3)

Definition of abbreviations: COPD = chronic obstructive pulmonary disease; FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity.

Data except number of subjects, sex and smoking status are expressed as median (range).

*4 non-COPD patients undergoing surgery for lung cancer and 1 healthy lung donor.

[†]Data healthy lung donor not available. [§]Data from 2 control subjects and 2 COPD patients are missing.

Table 2. Airway responsiveness to methacholine of intrapulmonary large and small airways in lung slices obtained from saline- and LPS-challenged guinea pigs and of intrapulmonary small airways in lung slices obtained from control subjects and COPD patients.

Group	Large airways		Small airways	
	E_{\max}	pD_2	E_{\max}	pD_2
	(% constriction)	(-log M)	(% constriction)	(-log M)
Guinea pig				
Saline-challenged	89.7 ± 4.5	5.83 ± 0.12	48.6 ± 5.4 ^{†††}	5.52 ± 0.25
LPS-challenged	98.3 ± 1.0*	6.47 ± 0.17**	72.7 ± 3.9 ^{***/†††}	5.88 ± 0.26 [†]
Human				
Control subjects			45.8 ± 11.1	5.68 ± 0.37
COPD patients			67.9 ± 3.2 [#]	5.77 ± 0.18

Definition of abbreviations: COPD = chronic obstructive pulmonary disease; E_{\max} = maximal effect; pD_2 = -log of the concentration causing 50% effect (-log EC_{50}); LPS = lipopolysaccharide. Data are presented as means ± SEM of 8-9 guinea pigs per group, 5 control subjects and 7 COPD patients.

* P < 0.05, ** P < 0.01 and *** P < 0.001 compared to saline-challenged guinea pigs. [†] P < 0.05, ^{†††} P < 0.001 compared to corresponding large airways. [#] P < 0.05 compared to control subjects.

Table 3. Biomechanical parameters fitted to the experimental dose-response curves using the multiscale biomechanical model of the airway embedded in parenchyma. Note that the parameters fitted to the guinea pig data required higher pre-stress (inflation pressure).

Airways	Wall thickness (χ)	ASM density/ muscarinic receptor density (β)	Collagen fiber density (C_1)	Strain-stiffening due to collagen recruitment (C_2)	Compressibility of parenchyma (ν)	Elastic modulus of airway wall relative to parenchyma (γ)
Human						
Control	0.3	5	0.25	1.0	0.4	5
COPD	0.3	5	0.05	0.14	0.1	100
Guinea pig						
Small airway - saline	0.27	9	0.2	1.0	0.4	2
Small airway – LPS (set 1)	0.3	9	0.05	0.09	0.1	100
Small airway – LPS (set 2)	0.38	9	0.05	0.09	0.1	100
large airway - saline	0.4	30	0.03	0.1	0.4	10

Definition of abbreviations: ASM = airway smooth muscle; COPD = chronic obstructive pulmonary disease; LPS = lipopolysaccharide.

LEGENDS TO THE FIGURES

Fig. 1. Airway responsiveness towards methacholine (MCh) of (A) large and (B) small intrapulmonary airways in lung slices obtained from male guinea pigs challenged with either saline or LPS, twice weekly for 12 weeks. Data represent means \pm SEM of 8-9 animals per group. *** $P < 0.001$ between curves.

Fig. 2. (A) α -SMA-positive area of large and small airways in lung slices obtained from male guinea pigs challenged with either saline or LPS, twice weekly for 12 weeks. Representative pictures are shown for each group and airway classification (A = airway and V = vessel). The bar indicates 500 μ m for the large airways and 200 μ m for the small airways. (B) Correlations between airway smooth muscle mass (α -SMA-positive area) and airway responsiveness (pD_2 , upper panels and E_{max} , lower panels) of large and small airways. Data represent means \pm SEM of 7-10 animals per group. *** $P < 0.001$ compared to large airways. (C) Effects of repeated saline or LPS challenge on alveolar airspace size (mean linear intercept; MLI) in male guinea pig lung slices obtained from guinea pigs challenged with either saline or LPS, twice weekly for 12 weeks. (D) Correlations between MLI and airway responsiveness (pD_2 , upper panels and E_{max} , lower panels) of large and small airways. Data represent means \pm SEM of 8-10 animals per group.

Fig. 3. Airway responsiveness towards methacholine (MCh) of peripheral airways in lung slices obtained from control subjects and from patients with COPD. Data represent means \pm SEM of 5 control subjects and 7 COPD patients. ** $P < 0.01$ between curves.

Fig. 4. (A) α -SMA-positive area in lung slices obtained from control subjects and COPD patients. Representative pictures are shown for control (top) and COPD (bottom). Data represent means \pm SEM of 5 control subjects and 6 COPD patients. (B) Alveolar airspace size (mean linear intercept; MLI) in lung slices of control subjects and COPD patients. Data represent means \pm SEM of 5 control subjects and 7 COPD patients. * $P < 0.05$ compared to control. (C) Correlations between airway smooth muscle mass (α -SMA-positive area) and airway responsiveness (pD_2 , upper panel and E_{max} , lower panel). (D) Correlations between MLI and airway responsiveness (pD_2 , upper panel and E_{max} , lower panel).

Fig. 5. (A) Schematic overview of our previously developed multiscale mathematical model (11) for which a given agonist concentration k_1 (model input) causes ASM cell shortening via acto-myosin cross-bridge interactions at the cell level, thereby generating airway narrowing at the tissue level. This allows to predict the lumen radius (r) at each concentration (k_1) to generate dose-response curves for a given set of parameter values for airway and parenchymal mechanical properties and cell properties listed above. Note that additional outputs are also generated by the model, such as radial and circumferential tissue stresses (τ) and contractile force at the cell-level (A), but the most direct comparison with experimental data is via the lumen radius. Multiple simulations were performed in which the parameters were varied within a range until a dose-response curve (k_1 vs r) is generated that best fits the baseline/control experimental data. Once this fit (a set of baseline parameters) is obtained, the parameter values are varied one at a time to identify those factors that contribute the most to the modified dose-response curves of the LPS/COPD data. (B) Simulated concentration-contraction curves (solid lines) for human control data and COPD data (from Fig. 3). Inflation pressure for these simulations was set as zero. In

705 the simulation, the effect of an increased γ , a reduced C1, a reduced C2 and a
706 reduced v individually as well as the combination of all the parameters were tested
707 ('combination'). (C) Simulated dose-response curves (solid lines) for saline- and LPS-
708 treated guinea pig slices for small airways with different wall thickness parameters
709 (Parameter sets 1 and 2; experimental data from Fig. 1B). (D) Simulated dose-
710 response curves (solid lines) for saline-treated guinea pig slices for large airways
711 (experimental data from Fig. 1A). Parameter values for the simulated curves are
712 given in Table 3.

FIGURES

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

